Picture 1 of 1
Stock photo
Picture 1 of 1
Stock photo
Malignant : How Bad Policy and Bad Evidence Harm People with Cancer by Vinayak K. Prasad (2020, Hardcover)
Rarewaves (662996)
98.5% positive feedback
Price:
US $48.81
ApproximatelyRM 208.82
+ $3.99 shipping
Returns:
30 days return. Buyer pays for return shipping. If you use an eBay shipping label, it will be deducted from your refund amount.
Condition:
Oops! Looks like we're having trouble connecting to our server.
Refresh your browser window to try again.
About this product
Product Identifiers
PublisherJohns Hopkins University Press
ISBN-101421437635
ISBN-139781421437637
eBay Product ID (ePID)8038584445
Product Key Features
Number of Pages304 Pages
Publication NameMalignant : How Bad Policy and Bad Evidence Harm People with Cancer
LanguageEnglish
SubjectEthics, Chemotherapy, Medical Law & Legislation, Oncology, Pharmacology, Health Policy
Publication Year2020
TypeTextbook
Subject AreaLaw, Medical
AuthorVinayak K. Prasad
FormatHardcover
Dimensions
Item Height1 in
Item Weight19.2 Oz
Item Length9.2 in
Item Width6.2 in
Additional Product Features
Intended AudienceScholarly & Professional
LCCN2019-027982
Dewey Edition23
ReviewsAimed at general readers (including patients), oncology trainees and experts in health-care policy, it informs and disturbs throughout., An insightful, well-written, and important book. Prasad has amasterful understanding of theissues he presents, weavingthem into a compelling story.--Christopher Booth, MD,Queen's University at Kingston Cancer Research Institute|9781421437637|, [ Malignant is] so applicable to the issues of the pandemic... Because what we're seeing is a research infrastructure that is not set up to do rapid evaluation, and to be resilient and to respond to a health crisis., "Patients should ask their oncologist how good the cure is: do I really live longer and better than doing "nothing"? Let them start by asking whether their doctor has read Prasad's book.", Malignant is punchy and persuasive, and the author is clearly in command of his subject matter. Prasad offers valuable advice on how to keep up with research as well as the appropriate way to analyse clinical trial reports.
Grade FromCollege Graduate Student
IllustratedYes
Dewey Decimal616.99/4061
Table Of ContentAcknowledgmentsIntroduction Part I. Cancer Drugs: The Outcomes They Improve and at What PriceChapter 1. The Basics of Cancer Drugs: Cost, Benefit, Value Chapter 2. Surrogate Endpoints in Cancer: What Are They and Where Are They Used? Chapter 3. The Use and Misuse of Surrogate Endpoints for Drug Approvals Chapter 4. How High Prices Harm Patients and Society Part II. Societal Forces That Distort Cancer MedicineChapter 5. Hype, Spin, and the Unbridled Enthusiasm That Distorts Cancer MedicineChapter 6. Financial Conflict of InterestChapter 7. The Harms of Financial Conflicts and How to Rehabilitate MedicineChapter 8. Will Precision Oncology Save Us? Part III. How to Interpret Cancer Evidence and TrialsChapter 9. Study Design 201Chapter 10. Principles of Oncology PracticeChapter 11. Important Trials in OncologyChapter 12. Global Oncology Part IV. SolutionsChapter 13. How Should Cancer Drug Development Proceed?Chapter 14. What Can Three Federal Agencies Do Tomorrow? Chapter 15. What Can People with Cancer Do?Chapter 16. What Can Students, Residents, and Fellows Do? Epilogue: The Hallmarks of Successful Cancer PolicyGlossary ReferencesIndex
SynopsisEach week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel--but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant , hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology is practiced. Throughout this work, Prasad illuminates deceptive practices which - promote novel cancer therapies long before credible data are available to support such treatment - exaggerate the potential benefits of new therapies, many of which cost thousands and in some cases hundreds of thousands of dollars Prasad then critiques the financial conflicts of interest that pervade the oncology field, the pharmaceutical industry, and the US Food and Drug administration. This is a book about how the actions of human beings--our policies, our standards of evidence, and our drug regulation--incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices. Prasad takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price. Ultimately, Prasad says, - more cancer clinical trials should measure outcomes that actually matter to people with cancer; - patients on those trials should look more like actual global citizens; - we need drug regulators to raise, not perpetually lower, the bar for approval; and - we need unbiased patient advocates and experts. This well-written, opinionated, and engaging book explains what we can do differently to make serious and sustained progress against cancer--and how we can avoid repeating the policy and practice mistakes of the past., Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel'but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology is practiced. Throughout this work, Prasad illuminates deceptive practices which promote novel cancer therapies long before credible data are available to support such treatment exaggerate the potential benefits of new therapies, many of which cost thousands and in some cases hundreds of thousands of dollars Prasad then critiques the financial conflicts of interest that pervade the oncology field, the pharmaceutical industry, and the US Food and Drug administration. This is a book about how the actions of human beings'our policies, our standards of evidence, and our drug regulation'incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices. Prasad takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price. Ultimately, Prasad says, more cancer clinical trials should measure outcomes that actually matter to people with cancer; patients on those trials should look more like actual global citizens; we need drug regulators to raise, not perpetually lower, the bar for approval; and we need unbiased patient advocates and experts. This well-written, opinionated, and engaging book explains what we can do differently to make serious and sustained progress against cancer - and how we can avoid repeating the policy and practice mistakes of the past., How hype, money, and bias can mislead the public into thinking that many worthless or unproven treatments are effective. Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel--but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant , hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology is practiced. Throughout this work, Prasad illuminates deceptive practices which * promote novel cancer therapies long before credible data are available to support such treatment; and * exaggerate the potential benefits of new therapies, many of which cost thousands and in some cases hundreds of thousands of dollars. Prasad then critiques the financial conflicts of interest that pervade the oncology field, the pharmaceutical industry, and the US Food and Drug administration. This is a book about how the actions of human beings--our policies, our standards of evidence, and our drug regulation--incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices. Prasad takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price. Ultimately, Prasad says, * more cancer clinical trials should measure outcomes that actually matter to people with cancer; * patients on those trials should look more like actual global citizens; * we need drug regulators to raise, not perpetually lower, the bar for approval; and * we need unbiased patient advocates and experts. This well-written, opinionated, and engaging book explains what we can do differently to make serious and sustained progress against cancer--and how we can avoid repeating the policy and practice mistakes of the past., How hype, money, and bias can mislead the public into thinking that many worthless or unproven treatments are effective. Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel--but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant , hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology is practiced. Throughout this work, Prasad illuminates deceptive practices which - promote novel cancer therapies long before credible data are available to support such treatment; and - exaggerate the potential benefits of new therapies, many of which cost thousands and in some cases hundreds of thousands of dollars. Prasad then critiques the financial conflicts of interest that pervade the oncology field, the pharmaceutical industry, and the US Food and Drug administration. This is a book about how the actions of human beings--our policies, our standards of evidence, and our drug regulation--incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices. Prasad takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price. Ultimately, Prasad says, - more cancer clinical trials should measure outcomes that actually matter to people with cancer; - patients on those trials should look more like actual global citizens; - we need drug regulators to raise, not perpetually lower, the bar for approval; and - we need unbiased patient advocates and experts. This well-written, opinionated, and engaging book explains what we can do differently to make serious and sustained progress against cancer--and how we can avoid repeating the policy and practice mistakes of the past., Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel'but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In ......
LC Classification NumberRC271.C5
Be the first to write a review
